DK1618889T3 - Influenzavaccine - Google Patents

Influenzavaccine

Info

Publication number
DK1618889T3
DK1618889T3 DK05077465.2T DK05077465T DK1618889T3 DK 1618889 T3 DK1618889 T3 DK 1618889T3 DK 05077465 T DK05077465 T DK 05077465T DK 1618889 T3 DK1618889 T3 DK 1618889T3
Authority
DK
Denmark
Prior art keywords
antigen
influenza vaccine
vaccine
dose
combination
Prior art date
Application number
DK05077465.2T
Other languages
Danish (da)
English (en)
Inventor
Hondt Erik D
Norbert Hehme
Original Assignee
Glaxosmithkline Biolog Sa
Glaxosmithkline Biolog Niederlassung Der Smithkline Beecham Pharma Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1618889(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa, Glaxosmithkline Biolog Niederlassung Der Smithkline Beecham Pharma Gmbh & Co Kg filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1618889T3 publication Critical patent/DK1618889T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05077465.2T 1999-09-30 2000-09-27 Influenzavaccine DK1618889T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923176.3A GB9923176D0 (en) 1999-09-30 1999-09-30 Novel composition
EP00966084A EP1216053B1 (en) 1999-09-30 2000-09-27 Influenza vaccine

Publications (1)

Publication Number Publication Date
DK1618889T3 true DK1618889T3 (da) 2011-06-06

Family

ID=10861908

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05077465.2T DK1618889T3 (da) 1999-09-30 2000-09-27 Influenzavaccine
DK00966084T DK1216053T3 (da) 1999-09-30 2000-09-27 Influenzavaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00966084T DK1216053T3 (da) 1999-09-30 2000-09-27 Influenzavaccine

Country Status (15)

Country Link
US (2) US7238349B1 (enExample)
EP (4) EP3103473A1 (enExample)
JP (4) JP2003510291A (enExample)
AT (2) ATE499113T1 (enExample)
AU (1) AU774921B2 (enExample)
BR (1) BR0014386A (enExample)
CA (2) CA2616210C (enExample)
CY (2) CY1111908T1 (enExample)
DE (3) DE60045668D1 (enExample)
DK (2) DK1618889T3 (enExample)
ES (2) ES2250193T3 (enExample)
GB (1) GB9923176D0 (enExample)
HK (1) HK1048434B (enExample)
PT (1) PT1618889E (enExample)
WO (1) WO2001022992A2 (enExample)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20050106178A1 (en) * 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
AU2004263813B8 (en) * 2003-02-25 2008-09-11 Medimmune, Llc Methods of producing influenza vaccine compositions
AU2012201973B2 (en) * 2003-02-25 2014-05-22 Medimmune, Llc Methods of producing influenza vaccine compositions
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
WO2005107797A1 (en) 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
SI2578229T1 (sl) 2004-09-09 2013-10-30 Novartis Vaccines And Diagnostics Gmbh Zmanjšanje potencialnih iatrogenih tveganj, povezanih z antigeni cepiv
WO2006062637A2 (en) 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics Inc. Influenza vaccination
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TW200700078A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568210A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
KR101211386B1 (ko) * 2005-11-04 2012-12-13 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. 알루미늄 보조제에 즉석 흡착되는 인플루엔자 백신
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
NZ567980A (en) * 2005-11-04 2012-01-12 Novartis Vaccines & Diagnostic Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
US8697087B2 (en) 2005-11-04 2014-04-15 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052059A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Changing th1/th2 balance in split influenza vaccines with adjuvants
AU2006310337B9 (en) 2005-11-04 2013-11-28 Novartis Ag Adjuvanted influenza vaccines including cytokine-inducing agents
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
US9072701B2 (en) * 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US20090220545A1 (en) * 2006-06-15 2009-09-03 Novartis Ag Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen
CA2583555C (en) * 2006-07-17 2020-01-07 Glaxosmithkline Biologicals S.A. Influenza vaccine
PL2422810T3 (pl) * 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
MX2009000660A (es) * 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
JP5954921B2 (ja) 2006-09-11 2016-07-20 ノバルティス アーゲー 卵を使用しないインフルエンザウイルスワクチンの作製
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
WO2008068631A2 (en) * 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
JP5666905B2 (ja) 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
CN101085348B (zh) * 2007-06-18 2010-08-18 南京农业大学 用于禽流感灭活抗原的鼻腔免疫复合佐剂
EA201070066A1 (ru) 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2692149A1 (en) * 2007-06-29 2009-01-08 Avianax, Llc Vaccine production for pathogenic bird viral diseases
WO2009014919A2 (en) * 2007-07-13 2009-01-29 Iowa State University Research Foundation, Inc. H2n3 influenza a viruses and methods of use
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2227251A1 (en) 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5415449B2 (ja) 2007-12-24 2014-02-12 ノバルティス アーゲー 吸着されたインフルエンザワクチンのためのアッセイ
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice
WO2009109550A1 (en) 2008-03-05 2009-09-11 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
AU2009227674C1 (en) * 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EP3023107A1 (en) * 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsion influenza vaccine
JP5715051B2 (ja) * 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
JP5712126B2 (ja) 2008-06-25 2015-05-07 ノバルティス アーゲー 遅延型追加刺激免疫処置に対する迅速な応答
EP2318044B1 (en) 2008-08-01 2015-12-02 Gamma Vaccines Pty Limited Influenza vaccines
RU2400536C1 (ru) * 2009-01-11 2010-09-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУП ГНЦ ВБ "Вектор" Роспотребнадзора) ШТАММ ВИРУСА ГРИППА ПТИЦ A/common gull/Chany/2006 H5N1 СУБТИПА ДЛЯ ПРИГОТОВЛЕНИЯ АНТИГЕНСОДЕРЖАЩЕГО ДИАГНОСТИЧЕСКОГО ИЛИ ВАКЦИННОГО ПРЕПАРАТА
US9278126B2 (en) 2009-02-10 2016-03-08 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010125461A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
EP2435066B1 (en) 2009-05-29 2013-11-20 Novartis AG Assays for influenza virus hemagglutinins
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
ES2538474T3 (es) * 2009-09-25 2015-06-22 Glaxosmithkline Biologicals S.A. Ensayo de inmunodifusión para el virus de la gripe
RU2012117610A (ru) 2009-10-09 2013-11-20 СиБАЙО ЛИМИТЕД Варианты шаперонина 10
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
NZ600254A (en) 2009-12-03 2013-10-25 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
PT2343052E (pt) 2009-12-03 2013-08-28 Novartis Ag Filtração hidrofílica durante o fabrico de adjuvantes de vacinas
CL2012001399A1 (es) 2009-12-03 2013-03-08 Novartis Ag Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion.
DK2356983T3 (da) 2009-12-03 2013-03-11 Novartis Ag Cirkulation af bestanddele under homogenisering af emulsioner
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
PT3103784T (pt) 2010-05-12 2019-05-20 Novartis Ag Preparação de uma emulsão óleo-em-água que compreende esqualeno
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinações adjuvantes de proteínas de ligação de fator h meningocócico
JP6165231B2 (ja) 2012-03-23 2017-07-19 ピットニー・ファーマシューティカルズ・ピーティーワイ・リミテッド 癌の治療のためのキナーゼ阻害剤
IN2014DN10408A (enExample) 2012-06-05 2015-08-14 Univ Australian
MX360120B (es) 2012-08-03 2018-10-23 Sanofi Pasteur Produccion de virus infecciosos de influenza.
CA2881325C (en) 2012-08-06 2020-09-29 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP6502853B2 (ja) 2012-12-17 2019-04-17 ニューサウス イノベイションズ ピーティーワイ リミテッド ムチンが関与する疾患の処置
NZ629700A (en) 2012-12-24 2017-01-27 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2523614C1 (ru) * 2013-04-09 2014-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Вакцина против гриппа и способ ее получения
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US10286062B2 (en) * 2013-07-09 2019-05-14 Texas Tech University System Universal influenza vaccine
CN105452350A (zh) * 2013-07-31 2016-03-30 株式会社可乐丽 透明性、抑制热裂现象优异的聚乙烯醇缩醛薄膜
ES2861806T3 (es) 2014-12-02 2021-10-06 Novartis Ag Fabricación de composiciones que contienen tensioactivo
WO2016149771A1 (en) 2015-03-26 2016-09-29 Gamma Vaccines Pty Limited Streptococcal vaccine
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
CN108027371B (zh) 2015-07-07 2020-08-18 思齐乐 流感效力试验
CN105251002B (zh) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 一种水包油型纳米乳佐剂及其mrsa纳米乳佐剂疫苗和制备方法
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
PE20212205A1 (es) 2017-09-08 2021-11-18 Maverick Therapeutics Inc Proteinas de union condicionalmente activadas restringidas
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
JP2023532944A (ja) 2020-06-30 2023-08-01 セキラス ユーケー リミテッド 水中油型エマルジョンアジュバントの低温濾過
CN111803625B (zh) * 2020-09-09 2020-12-18 天津中逸安健生物科技有限公司 一种亚单位流感疫苗裂解剂及其应用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD155875A1 (de) 1980-12-31 1982-07-14 Willy Nordheim Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes
DD211444A3 (de) 1982-08-19 1984-07-11 Saechsisches Serumwerk Verfahren zur herstellung von influenza-impfstoffen
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
DD300833A7 (de) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) * 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
AU6141094A (en) * 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5776468A (en) * 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US6387378B1 (en) * 1993-09-09 2002-05-14 George P. Shibley Device for storage and mucosal delivery of biological or pharmaceutical materials to animals
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
BR9506885A (pt) * 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
CA2277911C (en) * 1997-01-13 2010-09-14 Emory University Compounds and their combinations for the treatment of influenza infection
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1035867A1 (en) * 1997-12-02 2000-09-20 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
CA2324504A1 (en) * 1998-03-20 1999-09-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
TR200200776T2 (tr) * 1999-09-24 2002-06-21 Smithkline Beecham Biologicals S.A. Burun içi grip virüsü aşısı.
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
TW200700078A (en) * 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Novel use
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
MX2009000660A (es) * 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
PL2422810T3 (pl) * 2006-07-17 2015-03-31 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition

Also Published As

Publication number Publication date
EP1216053B1 (en) 2005-11-16
EP2269637A1 (en) 2011-01-05
BR0014386A (pt) 2002-06-18
EP1618889B8 (en) 2011-04-20
JP2003510291A (ja) 2003-03-18
DE60024112T2 (de) 2006-08-24
HK1048434A1 (en) 2003-04-04
AU7660200A (en) 2001-04-30
GB9923176D0 (en) 1999-12-01
DE60045668D1 (de) 2011-04-07
ATE499113T1 (de) 2011-03-15
CA2386014A1 (en) 2001-04-05
CA2616210C (en) 2014-05-06
EP1618889A3 (en) 2006-06-14
US20070141078A1 (en) 2007-06-21
EP1216053A2 (en) 2002-06-26
ES2250193T3 (es) 2006-04-16
HK1048434B (en) 2006-07-28
DE60024112D1 (de) 2005-12-22
CA2386014C (en) 2014-05-13
WO2001022992A3 (en) 2001-05-17
EP1618889A2 (en) 2006-01-25
JP2012021030A (ja) 2012-02-02
AU774921B2 (en) 2004-07-15
CA2616210A1 (en) 2001-04-05
WO2001022992A2 (en) 2001-04-05
EP3103473A1 (en) 2016-12-14
EP1618889B1 (en) 2011-02-23
PT1618889E (pt) 2011-05-10
ES2359982T3 (es) 2011-05-30
DE122011100035I1 (de) 2011-12-15
US7238349B1 (en) 2007-07-03
DK1216053T3 (da) 2006-03-20
JP2008001725A (ja) 2008-01-10
CY2011008I1 (el) 2014-04-09
CY2011008I2 (el) 2014-04-09
JP2014205726A (ja) 2014-10-30
CY1111908T1 (el) 2014-04-09
ATE309821T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DK1216053T3 (da) Influenzavaccine
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
MXPA05009580A (es) Vacuna contra el virus de la influenza.
WO2002024876A3 (en) Live influenza vaccine and method of manufacture
EP1270016A4 (en) VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
JP2009539965A5 (enExample)
GB2386072A (en) Novel vaccine
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
EA200301151A1 (ru) Вакцина против натуральной оспы
MX2024003337A (es) Composiciones inmunogenicas contra la influenza.
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
MY153290A (en) Multivalent avian influenza vaccines
WO2008115785A3 (en) Multivalent avian influenza vaccines and methods
DK1401492T3 (da) LTB4 som vaccineadjuvans
ATE330969T1 (de) Impfstoffe basierend auf mutanten des virus der infektiösen bursal-krankheit
MX2024003507A (es) Mutantes del virus de la influenza b y usos de los mismos.
UA62746C2 (en) Emulsion vaccine associated inactivated against newcastle disease, infectious bronchitis of fowls, and syndrome of decreasing egg production-76
DE60233391D1 (de) Vakzine zum schutz von tieren gegen leishmania